Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction ('PCR')-based manufacturing platform that allows for the large-scale production of specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company's deep expertise in DNA.
The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
Company profile
Ticker
APDN
Exchange
Website
CEO
James Hayward
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DATALINK CAPITAL CORP/TX/, DCC ACQUISITION CORP, PROHEALTH MEDICAL TECHNOLOGIES INC
SEC CIK
Corporate docs
Subsidiaries
APDN (B.V.I.) Inc. • Applied DNA Sciences Europe Limited • Applied DNA Sciences India Private Limited • LineaRX, Inc. • Applied DNA Clinical Labs LLC ...
IRS number
592262718
APDN stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
28 Feb 23
8-K
Results of Operations and Financial Condition
9 Feb 23
10-Q
2023 Q1
Quarterly report
9 Feb 23
10-K/A
2022 FY
Annual report (amended)
27 Jan 23
8-K
Applied DNA Announces Fourth Quarter and Fiscal Year
14 Dec 22
10-K
2022 FY
Annual report
14 Dec 22
8-K
Submission of Matters to a Vote of Security Holders
23 Sep 22
8-K
Applied DNA Reports Third Quarter Fiscal 2022 Financial Results
11 Aug 22
10-Q
2022 Q3
Quarterly report
11 Aug 22
DEF 14A
Definitive proxy
10 Aug 22
Transcripts
APDN
Earnings call transcript
2023 Q1
9 Feb 23
APDN
Earnings call transcript
2022 Q4
17 Dec 22
APDN
Earnings call transcript
2022 Q2
14 May 22
APDN
Earnings call transcript
2022 Q1
10 Feb 22
APDN
Earnings call transcript
2021 Q4
10 Dec 21
APDN
Earnings call transcript
2021 Q3
13 Aug 21
APDN
Earnings call transcript
2021 Q2
14 May 21
APDN
Earnings call transcript
2021 Q1
12 Feb 21
APDN
Earnings call transcript
2020 Q4
18 Dec 20
APDN
Earnings call transcript
2020 Q4
17 Dec 20
Latest ownership filings
SC 13G
AWM Investment Company, Inc.
14 Feb 23
SC 13G/A
Grossman Bruce
9 Feb 23
4
YACOV A SHAMASH
27 Jan 23
4
Scott L Anchin
27 Jan 23
4
Joseph D. Ceccoli
27 Jan 23
4
Sanford R Simon
27 Jan 23
4
Elizabeth M Schmalz
27 Jan 23
4
ROBERT B CATELL
27 Jan 23
SC 13G/A
CVI Investments, Inc.
14 Feb 22
SC 13D
Hayward James A
14 Feb 22
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 12.88 mm | 12.88 mm | 12.88 mm | 12.88 mm | 12.88 mm | 12.88 mm |
| Cash burn (monthly) | 779.37 k | (no burn) | 1.28 mm | 1.09 mm | 794.37 k | 638.16 k |
| Cash used (since last report) | 2.06 mm | n/a | 3.39 mm | 2.88 mm | 2.10 mm | 1.69 mm |
| Cash remaining | 10.81 mm | n/a | 9.49 mm | 10.00 mm | 10.78 mm | 11.19 mm |
| Runway (months of cash) | 13.9 | n/a | 7.4 | 9.2 | 13.6 | 17.5 |
Institutional ownership, Q3 2022
13.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 32 |
| Opened positions | 16 |
| Closed positions | 9 |
| Increased positions | 9 |
| Reduced positions | 3 |
| 13F shares | Current |
|---|---|
| Total value | 1.98 mm |
| Total shares | 1.77 mm |
| Total puts | 509.30 k |
| Total calls | 183.20 k |
| Total put/call ratio | 2.8 |
| Largest owners | Shares | Value |
|---|---|---|
| AWM Investment | 400.00 k | $452.00 k |
| Vanguard | 353.05 k | $399.00 k |
| Citadel Advisors | 161.31 k | $182.00 k |
| Sabby Management | 132.69 k | $150.00 k |
| Two Sigma Investments | 128.83 k | $146.00 k |
| BLK Blackrock | 101.66 k | $114.00 k |
| Geode Capital Management | 100.46 k | $113.00 k |
| Susquehanna International | 74.66 k | $84.00 k |
| MS Morgan Stanley | 69.36 k | $79.00 k |
| Atria Wealth Solutions | 62.86 k | $71.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 Jan 23 | Catell Robert B | NQSO Common Stock | Grant | Acquire A | No | No | 1.41 | 39,428 | 55.59 k | 39,428 |
| 25 Jan 23 | Catell Robert B | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 75,099 | 105.89 k | 75,099 |
| 25 Jan 23 | Ferguson Elizabeth M. | NQSO Common Stock | Grant | Acquire A | No | No | 1.41 | 40,366 | 56.92 k | 40,366 |
| 25 Jan 23 | Ferguson Elizabeth M. | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 75,099 | 105.89 k | 75,099 |
| 25 Jan 23 | Ceccoli Joseph D. | NQSO Common Stock | Grant | Acquire A | No | No | 1.41 | 41,305 | 58.24 k | 41,305 |
| 25 Jan 23 | Ceccoli Joseph D. | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 75,099 | 105.89 k | 75,099 |
| 25 Jan 23 | Simon Sanford R | NQSO Common Stock | Grant | Acquire A | No | No | 1.41 | 38,489 | 54.27 k | 38,489 |
| 25 Jan 23 | Simon Sanford R | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 75,099 | 105.89 k | 75,099 |
| 25 Jan 23 | Anchin Scott L | NQSO Common Stock | Grant | Acquire A | No | No | 1.41 | 37,550 | 52.95 k | 37,550 |
| 25 Jan 23 | Anchin Scott L | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 75,099 | 105.89 k | 75,099 |
News
Applied DNA Sciences's Return On Capital Employed Insights
13 Feb 23
HC Wainwright & Co. Reiterates Buy on Applied DNA Sciences, Maintains $5 Price Target
10 Feb 23
Applied DNA Announces New York State Award Valued At Up To $1.5M To Support Establishment Of cGMP linearDNA Production Capacity On Long Island, New York
10 Feb 23
12 Health Care Stocks Moving In Thursday's After-Market Session
9 Feb 23
Applied DNA Sciences Q1 EPS $(0.30) Misses $(0.29) Estimate, Sales $5.26M Beat $4.17M Estimate
9 Feb 23
Press releases
Applied DNA Announces New York State Award Valued at Up To $1.5 Million to Support Establishment of cGMP linearDNA™ Production Capacity on Long Island, New York
10 Feb 23
Applied DNA Reports First Quarter Fiscal 2023 Financial Results
9 Feb 23
Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
5 Jan 23